Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -144.16% is 14% above its 5-year average of -167.74%, near the high end of its 5-year range (-153792.31%–51.16%).
99.79% above its 12-month average of -69064.21%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2026 (2026-03-31): -77.83%.
EBITDA MARGIN
-144.16%
EBITDA MARGIN AVG TTM
-69064.21%
EBITDA MARGIN AVG 3Y
-769.57%
EBITDA MARGIN AVG 5Y
-167.74%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+99.79%
CURRENT VS 3Y AVG
+81.27%
CURRENT VS 5Y AVG
+14.06%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Precision BioSciences, Inc.
Market Cap
$173.89M
EBITDA Margin
-144.16%
TTM Avg
-69064.21%
3Y Avg
-769.57%
5Y Avg
-167.74%
Market Cap
$172.65M
EBITDA Margin
-138.09%
TTM Avg
-113.30%
3Y Avg
-81.67%
5Y Avg
-67.39%
Market Cap
$177.22M
EBITDA Margin
-6455.53%
TTM Avg
-6455.53%
3Y Avg
-6455.53%
5Y Avg
-6455.53%
Market Cap
$178.56M
EBITDA Margin
-83.89%
TTM Avg
-252.72%
3Y Avg
-1380.70%
5Y Avg
-1383.45%
Market Cap
$179.31M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$165.46M
EBITDA Margin
-416.41%
TTM Avg
-228.13%
3Y Avg
-163.44%
5Y Avg
-116.60%
Market Cap
$182.88M
EBITDA Margin
-6.19%
TTM Avg
-12.15%
3Y Avg
-13.37%
5Y Avg
-13.97%
Market Cap
$160.80M
EBITDA Margin
-3676.90%
TTM Avg
-2033.97%
3Y Avg
-1569.70%
5Y Avg
-1569.70%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Precision BioSciences, Inc. (DTIL) | $173.89M | -144.16% | -69064.21% | -769.57% | -167.74% |
| MediWound Ltd. (MDWD)vs › | $172.65M | -138.09% | -113.30% | -81.67% | -67.39% |
| Compass Therapeutics, Inc. (CMPX)vs › | $177.22M | -6455.53% | -6455.53% | -6455.53% | -6455.53% |
| Cue Biopharma, Inc. (CUE)vs › | $178.56M | -83.89% | -252.72% | -1380.70% | -1383.45% |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.31M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $165.46M | -416.41% | -228.13% | -163.44% | -116.60% |
| Journey Medical Corporation (DERM)vs › | $182.88M | -6.19% | -12.15% | -13.37% | -13.97% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $160.80M | -3676.90% | -2033.97% | -1569.70% | -1569.70% |
| Inogen, Inc. (INGN)vs › | $159.74M | -2.74% | -4.58% | -13.60% | -7.28% |
| Anavex Life Sciences Corp. (AVXL)vs › | $158.01M | N/A | N/A | N/A | N/A |
Gross Margin
100.0%
EBITDA Margin
-144.2%
Operating Margin
-152.2%
Net Margin
-117.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | -77.83% |
| 2025-12-31 | 38.55% |
| 2025-09-30 | -153792.31% |
| 2025-06-30 | -117672.22% |
| 2025-03-31 | -73817.24% |
| 2024-12-31 | -3775.71% |
| 2024-09-30 | -3518.06% |
| 2024-06-30 | 51.16% |
| 2024-03-31 | -15.70% |
| 2023-12-31 | -189.46% |
| 2023-09-30 | -78.71% |
| 2023-06-30 | -3.76% |
| 2023-03-31 | -126.15% |
| 2022-12-31 | -92.79% |
| 2022-09-30 | -168.80% |
| 2022-06-30 | -716.62% |
| 2022-03-31 | -756.41% |
| 2021-12-31 | -445.75% |
| 2021-09-30 | -37.31% |
| 2021-06-30 | 35.31% |
| 2021-03-31 | -99.55% |
| 2020-12-31 | -237.50% |
| 2020-09-30 | -319.77% |
| 2020-06-30 | -2815.86% |
| 2020-03-31 | -358.76% |
| 2019-12-31 | -307.45% |
| 2019-09-30 | -422.96% |
| 2019-06-30 | -421.28% |
| 2019-03-31 | -339.71% |
| 2018-12-31 | -309.84% |
| 2018-09-30 | -388.11% |
| 2018-06-30 | -619.69% |
| 2018-03-31 | -574.41% |
